Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience

Tacar S. Y., Yilmaz M., Oz B., Tural D.

TUMORI JOURNAL, cilt.108, sa.3, ss.258-262, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 108 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1177/03008916211009303
  • Dergi Adı: TUMORI JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.258-262
  • Anahtar Kelimeler: MET amplification, lung cancer, crizotinib, CELL LUNG-CANCER, TYROSINE KINASE, CHEMOTHERAPY, RESISTANCE, INHIBITORS, MUTATIONS, GEFITINIB, OCCURS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Introduction: Lung cancer is the most common cause of cancer-related death in the world. Changes in the treatment of metastatic lung cancer in recent years have made targetable mutations gain importance. MET alteration is one of these driver mutations and crizotinib is a tyrosine kinase inhibitor used in therapy.